Selected References:
- Clowse M, et al. 2016. Pregnancy outcomes in the tofacitinib safety databases for rheumatoid arthritis and psoriasis. Drug Saf 39(8):755-762.
- Fernández-Sánchez M, et al. 2021. Fetal exposure to tofacitinib during the first trimester: A healthy newborn case report. Birth Defects Res 113(17):1275-1279.
- Mahadevan U, et al. 2018. Outcomes of pregnancies with maternal/paternal exposure in the tofacitinib safety databases for ulcerative colitis. Inflammatory Bowel Diseases 24(12):2494–2500.
- Mahadevan U, et al. 2019. Inflammatory bowel disease in pregnancy clinical care pathway: A report from the American Gastroenterological Association IBD Parenthood Project Working Group. Gastroenterology 156(5):1508-1524.
- Merren A, et al. 2015. THU0173 Pregnancy outcomes in the tofacitinib RA study database through April 2014. Annals of the Rheumatic Diseases 74:256-257.
- NIH (Last updated October 10, 2023). COVID-19 Treatment Guidelines: Janus Kinase Inhibitors. Available at https://www.covid19treatmentguidelines.nih.gov/therapies/immunomodulators/janus-kinase-inhibitors/ [Accessed December 2023].
- NIH (Last updated: October 10, 2023). Pregnancy, Lactation, and COVID-19 Therapeutics. Available online at: https://www.covid19treatmentguidelines.nih.gov/special-populations/pregnancy/pregnancy-lactation-and-covid-19-therapeutics/ [Accessed December 2023].
- Picardo S, Seow CH. 2019. A pharmacological approach to managing inflammatory bowel disease during conception, pregnancy and breastfeeding: Biologic and oral small molecule therapy. Drugs 79(10):1053-1063.
- Xeljanz/Xeljanz XR Prescribing Information (Last updated: 09/2023). Available online at: https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?setid=68e3d6b2-7838-4d2d-a417-09d919b43e13&type=pdf [Accessed December 2023].
